Clovis Oncology Inc (fka CLVSQ) (CLVSQ)

[XenaLives]

Clovis Oncology Inc. [CLVS] Revenue clocked in at $156.10 million, down -24.35% YTD: What’s Next?
By Caleb Clifford -February 10, 2022
Clovis Oncology Inc. [NASDAQ: CLVS] jumped around 0.16 points on Wednesday, while shares priced at $2.05 at the close of the session, up 8.47%. The company report on January 10, 2022 that Clovis Oncology Announces Preliminary Financial Results for the Fourth Quarter and Full Year 2021.

Estimated $35.5M – $36.1M in Rubraca® (rucaparib) global sales for Q4 2021 and $148.3M – $148.9M for FY 2021.

Continuing impact on ovarian cancer diagnoses and treatments from COVID-19.

Clovis Oncology Inc. stock is now -24.35% down from its year-to-date (YTD) trading value. CLVS Stock saw the intraday high of $2.09 and lowest of $1.91 per share. The company’s 52-week high price is 10.74, which means current price is +19.88% above from all time high which was touched on 01/03/22.

Compared to the average trading volume of 4.30M shares, CLVS reached a trading volume of 7530240 in the most recent trading day, which is why market watchdogs consider the stock to be active.

What do top market gurus say about Clovis Oncology Inc. [CLVS]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for CLVS shares is $5.33 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on CLVS stock is a recommendation set at 3.20. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

H.C. Wainwright have made an estimate for Clovis Oncology Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on May 18, 2020. The new note on the price target was released on April 27, 2020, representing the official price target for Clovis Oncology Inc. stock. Previously, the target price had yet another raise to $6, while BofA/Merrill analysts kept a Underperform rating on CLVS stock. On January 08, 2020, analysts decreased their price target for CLVS shares from 36 to 27.

The Average True Range (ATR) for Clovis Oncology Inc. is set at 0.20, with the Price to Sales ratio for CLVS stock in the period of the last 12 months amounting to 1.66.

How has CLVS stock performed recently?
Clovis Oncology Inc. [CLVS] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 9.04. With this latest performance, CLVS shares dropped by -20.85% in over the last four-week period, additionally sinking by -57.38% over the last 6 months – not to mention a drop of -78.51% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CLVS stock in for the last two-week period is set at 43.50, with the RSI for the last a single of trading hit 48.42, and the three-weeks RSI is set at 41.48 for Clovis Oncology Inc. [CLVS]. The present Moving Average for the last 50 days of trading for this stock 2.5900, while it was recorded at 1.8800 for the last single week of trading, and 4.3100 for the last 200 days.

Clovis Oncology Inc. [CLVS]: Deeper insight into the fundamentals
Clovis Oncology Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.90 and a Current Ratio set at 2.00.

https://dbtnews.com/2022/02/10/clovis-oncology-inc-clvs-revenue-clocked-in-at-156-10-million-down-24-35-ytd-whats-next/